Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial ExtensionCompanies: Regeneron PharmaceuticalsPasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP
- Regeneron entscheidet sich für Veeva Vault CRMCompanies: Regeneron PharmaceuticalsVeeva SystemsFührendes Biopharma-Unternehmen entscheidet sich für agentic CRM im Bereich Life Sciences zur Generierung von Commercial Evidence PLEASANTON, Kalifornien, 25. August 2026 -- Veeva Systems (NYSE: VEEV) gab heute bekannt, dass sich Regeneron Pharmaceuticals weltweit für Veeva...
- Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)Companies: Regeneron PharmaceuticalsFOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability